Head-To-Head Survey: Organovo (NASDAQ:ONVO) vs. Pharmacyte Biotech (NASDAQ:PMCB)

Organovo (NASDAQ:ONVO) and Pharmacyte Biotech (OTCMKTS:PMCB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.


This table compares Organovo and Pharmacyte Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Organovo -861.70% -70.01% -63.41%
Pharmacyte Biotech N/A -74.36% -66.54%

Institutional and Insider Ownership

43.0% of Organovo shares are owned by institutional investors. Comparatively, 0.1% of Pharmacyte Biotech shares are owned by institutional investors. 3.5% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Organovo has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, Pharmacyte Biotech has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Organovo and Pharmacyte Biotech, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organovo 0 0 2 0 3.00
Pharmacyte Biotech 0 0 0 0 N/A

Organovo presently has a consensus price target of $2.13, suggesting a potential upside of 333.67%. Given Organovo’s higher probable upside, analysts clearly believe Organovo is more favorable than Pharmacyte Biotech.

Earnings and Valuation

This table compares Organovo and Pharmacyte Biotech’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Organovo $3.09 million 18.95 -$26.64 million ($0.23) -2.13
Pharmacyte Biotech N/A N/A -$6.82 million N/A N/A

Pharmacyte Biotech has lower revenue, but higher earnings than Organovo.


Organovo beats Pharmacyte Biotech on 7 of the 9 factors compared between the two stocks.

About Organovo

Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.

About Pharmacyte Biotech

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.